CN1408406A - Medicinal composition for curing skin disease - Google Patents
Medicinal composition for curing skin disease Download PDFInfo
- Publication number
- CN1408406A CN1408406A CN02129689A CN02129689A CN1408406A CN 1408406 A CN1408406 A CN 1408406A CN 02129689 A CN02129689 A CN 02129689A CN 02129689 A CN02129689 A CN 02129689A CN 1408406 A CN1408406 A CN 1408406A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- weight
- portions
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine composition for treating skin diseases is prepared with astragalus root, white atractylodes rhizome, pilose antler, aweto, black-tail snake and other 17 kinds of Chinese medicinal materials. The present invention used in preventing and treating skin diseases and has high curative rate and no toxic side effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to the dermopathic pharmaceutical composition of a kind of treatment.
Background technology
Psoriasis is commonly called as psoriasis, is a kind of chronic, and outbreak is the intractable of characteristics, intractable dermatosis with the epidermis cell hyper-proliferative repeatedly, and the chronic dermatosis that easily recurs, and the lighter influences its outer table image, and weight person is threat to life health then.Bringing very for people's work, life and spirit seriously influences.At present, the research of its cause of disease is not still had final conclusion, but certainly not the superficial part mycete causes, and relevant with body's immunity, inherited genetic factors, Nervous and Mental Factors etc.At present, treat psoriatic method have multiple, as, take Chinese medicines such as Radix Tripterygii Wilfordii, but have death formerly, so unreliable.The patient who also has treat with the cyclosporin of import, but the side effect of this medicine is very big, can cause hepar damnification even hepatic necrosis.Traditional tcm therapy is controlled psoriasis mostly with heat clearing away, removing heat from blood, the method for invigorating blood circulation, and curative effect is slow, and cure rate is low.
Technology contents
The object of the present invention is to provide a kind ofly has remarkable result, and the pharmaceutical composition that has no side effect to the treatment psoriasis.
The present invention is achieved through the following technical solutions:
Choose crude drug:
Radix Astragali 30-90 weight portion Rhizoma Atractylodis Macrocephalae 15-45 weight portion
Cornu Cervi Pantotrichum 15-45 weight portion winter worm 30-90 weight portion
Zaocys 30-90 weight portion Flos Sophorae 30-90 weight portion
Eupolyphaga Seu Steleophaga 15-45 weight portion Rhizoma Chuanxiong 30-90 weight portion
Radix Rehmanniae 15-45 weight portion Radix Paeoniae Alba 15-45 weight portion
Radix Sophorae Flavescentis 15-45 weight portion Rhizoma Polygoni Cuspidati 10-30 weight portion
Radix Tripterygii Wilfordii 10-30 weight portion Rhizoma Smilacis Glabrae 30-90 weight portion
Flos Lonicerae 15-45 weight portion Radix Sophorae Tonkinensis 10-30 weight portion
Fructus Forsythiae 15-45 weight portion Calomelas 5-15 weight portion
Herba Epimedii 15-45 weight portion Radix Glycyrrhizae 15-45 weight portion
Radix Curcumae 5-15 weight portion Flos Carthami 10-30 weight portion
Optimum ratio of the present invention is:
The Radix Astragali 60 weight portion Rhizoma Atractylodis Macrocephalaes 30 weight portion Cornu Cervi Pantotrichums 30 weight portions
Winter worm 60 weight portion Zaocyss 60 weight portion Flos Sophorae 60 weight portions
The Eupolyphaga Seu Steleophaga 30 weight portion Rhizoma Chuanxiongs 60 weight portion Radix Rehmanniae 30 weight portions
The Radix Paeoniae Alba 30 weight portion Radix Sophorae Flavescentiss 30 weight portion Rhizoma Polygoni Cuspidati 20 weight portions
Radix Tripterygii Wilfordii 20 weight portion Rhizoma Smilacis Glabraes 60 weight portion Flos Loniceraes 30 weight portions
Radix Sophorae Tonkinensis 20 weight portion Fructus Forsythiaes 30 weight portion Calomelass 10 weight portions
Herba Epimedii 30 weight portion Radix Glycyrrhizaes 30 weight portion Radix Curcumaes 10 weight portions
Flos Carthami 20 weight portions
The present invention handles with traditional infusion and grinds to the powder, and is encapsulated.
It is monarch drug that the present invention adopts the Radix Astragali, Cornu Cervi Pantotrichum, winter worm, the Epimedium of warming YANG nourishing YIN QI invigorating to do the main force; With invigorate blood circulation, to do outer helping be ministerial drug for removing heat from blood, the Flos Carthami of enriching blood, Rhizoma Chuanxiong, Flos Sophorae, Eupolyphaga Seu Steleophaga, the Radix Paeoniae Alba; With the Radix Rehmanniae, Fructus Forsythiae, Rhizoma Smilacis Glabrae, Flos Lonicerae, Rhizoma Polygoni Cuspidati, Radix Tripterygii Wilfordii is adjuvant drug, the tight secret prescription that other controls psoriasis that is different from of prescription.
Medicine of the present invention (magical effect silver bits capsule) is cured the over one hundred routine patient of psoriasis, now clinical 52 complete examples is summarized as follows:
1, curative effect and result
Control male's 27 examples in 52 examples, women's 25 examples, minimum 12 years old of age altogether, maximum 75 years old.The shortest 2 months, the longest 35 years; Erythra is drop shape person 30 examples, map shape person 6 examples, irregular and plate-like 16 examples; Pain kitchen range the infected 18 examples; Humid environment person 13 examples; Emotional distress person's 9 examples; Family history 7 examples; Agnogenio 5 examples; Wherein 21 examples were once used interferon, Western medicine such as thymosin, FUFANG QINGDAI WAN, hormones, invalid or effectively after recurrence again.
Recovery from illness: the back erythra of taking medicine all disappears, clinical symptom disappearance, and 44 examples account for 85%
Effectively: the back skin of taking medicine disappears more than 80%, and clinical symptoms is improved, and 7 examples account for 14%
Invalid: the back skin lesion less than 50% that disappears of taking medicine; Or one course of treatment of less than of taking medicine, 1 example accounts for 1%
Total effective rate is 99%.
Embodiment
Radix Astragali 60g Rhizoma Atractylodis Macrocephalae 30g Cornu Cervi Pantotrichum 30g winter worm 60g
Zaocys 60g Flos Sophorae 60g Eupolyphaga Seu Steleophaga 30g Rhizoma Chuanxiong 60g
Radix Rehmanniae 30g Radix Paeoniae Alba 30g Radix Sophorae Flavescentis 30g Rhizoma Polygoni Cuspidati 20g
Radix Tripterygii Wilfordii 20g Rhizoma Smilacis Glabrae 60g Flos Lonicerae 30g Radix Sophorae Tonkinensis 20g
Fructus Forsythiae 30g Calomelas 10g Epimedium 30g Radix Glycyrrhizae 30g
Radix Curcumae 10g Flos Carthami 20g
Grind to the powder the dress zero capsule with traditional infusion processing.Every day 3-4 time, each 1-2 grain, one month is a course of treatment, one after each meal, boiled water takes, and period in a medicine is given up alcohol and maror, but child's decrement.
Claims (2)
1, the dermopathic pharmaceutical composition of a kind of treatment is characterized in that, said composition is to be made by following crude drug:
Radix Astragali 30-90 weight portion Rhizoma Atractylodis Macrocephalae 15-45 weight portion
Cornu Cervi Pantotrichum 15-45 weight portion winter worm 30-90 weight portion
Zaocys 30-90 weight portion Flos Sophorae 30-90 weight portion
Eupolyphaga Seu Steleophaga 15-45 weight portion Rhizoma Chuanxiong 30-90 weight portion
Radix Rehmanniae 15-45 weight portion Radix Paeoniae Alba 15-45 weight portion
Radix Sophorae Flavescentis 15-45 weight portion Rhizoma Polygoni Cuspidati 10-30 weight portion
Radix Tripterygii Wilfordii 10-30 weight portion Rhizoma Smilacis Glabrae 30-90 weight portion
Flos Lonicerae 15-45 weight portion Radix Sophorae Tonkinensis 10-30 weight portion
Fructus Forsythiae 15-45 weight portion Calomelas 5-15 weight portion
Herba Epimedii 15-45 weight portion Radix Glycyrrhizae 15-45 weight portion
Radix Curcumae 5-15 weight portion Flos Carthami 10-30 weight portion
2, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
The Radix Astragali 60 weight portion Rhizoma Atractylodis Macrocephalaes 30 weight portion Cornu Cervi Pantotrichums 30 weight portions
Winter worm 60 weight portion Zaocyss 60 weight portion Flos Sophorae 60 weight portions
The Eupolyphaga Seu Steleophaga 30 weight portion Rhizoma Chuanxiongs 60 weight portion Radix Rehmanniae 30 weight portions
The Radix Paeoniae Alba 30 weight portion Radix Sophorae Flavescentiss 30 weight portion Rhizoma Polygoni Cuspidati 20 weight portions
Radix Tripterygii Wilfordii 20 weight portion Rhizoma Smilacis Glabraes 60 weight portion Flos Loniceraes 30 weight portions
Radix Sophorae Tonkinensis 20 weight portion Fructus Forsythiaes 30 weight portion Calomelass 10 weight portions
Herba Epimedii 30 weight portion Radix Glycyrrhizaes 30 weight portion Radix Curcumaes 10 weight portions
Flos Carthami 20 weight portions
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021296898A CN1244370C (en) | 2002-09-12 | 2002-09-12 | Medicinal composition for curing skin disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021296898A CN1244370C (en) | 2002-09-12 | 2002-09-12 | Medicinal composition for curing skin disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1408406A true CN1408406A (en) | 2003-04-09 |
| CN1244370C CN1244370C (en) | 2006-03-08 |
Family
ID=4746330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021296898A Expired - Fee Related CN1244370C (en) | 2002-09-12 | 2002-09-12 | Medicinal composition for curing skin disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1244370C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843735B (en) * | 2009-11-04 | 2011-08-17 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating psoriasis |
| US20190262300A1 (en) * | 2016-10-17 | 2019-08-29 | Enzychem Lifesciences Corporation | Composition for preventing or treating psoriasis containing monoacetyl diacylglycerol compound |
-
2002
- 2002-09-12 CN CNB021296898A patent/CN1244370C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843735B (en) * | 2009-11-04 | 2011-08-17 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating psoriasis |
| US20190262300A1 (en) * | 2016-10-17 | 2019-08-29 | Enzychem Lifesciences Corporation | Composition for preventing or treating psoriasis containing monoacetyl diacylglycerol compound |
| JP2019534325A (en) * | 2016-10-17 | 2019-11-28 | エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Composition for preventing or treating psoriasis containing a monoacetyldiacylglycerol compound |
| JP2021169465A (en) * | 2016-10-17 | 2021-10-28 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | Composition for preventing or treating psoriasis containing monoacetyl diacylglycerol compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244370C (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028481A (en) | Medicinal liquor for treating hyperosteogeny and lumbar intervertebral disc protrusion | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1356138A (en) | Medicine for treating cardiovascular and cerebrovascular diseases of old people | |
| CN1286518C (en) | Chinese medicinal prescription for treating gastropathy | |
| CN1091609C (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
| CN1824205A (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN1931329A (en) | Stomatocase treating medicine | |
| CN1121866C (en) | Chinese medicine for treating man's sexual disfunction and its preparing process | |
| CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
| CN1657067A (en) | Chinese medicine for treating psoriasis | |
| CN1365819A (en) | Medicine for treating apoplexy | |
| CN101152540A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN1244370C (en) | Medicinal composition for curing skin disease | |
| CN1385191A (en) | Medicine for treating liver disease | |
| CN1057230C (en) | Traditional Chinese medicine capsule for treating thrombophlebitis | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN1331996A (en) | Hepatitis B treaitng pill | |
| CN1164294C (en) | Liver cancer resisting medicine | |
| CN1270768C (en) | Medicine for treating cold disease | |
| CN1055220C (en) | Chinese drug for treatment of hemiplegia | |
| CN101637536B (en) | Medicine for treating chronic sinusitis and preparation method thereof | |
| CN1698863A (en) | Chinese medicinal preparation for treating hyperosteogeny | |
| CN101152542A (en) | Traditional Chinese medicine for treating cholestatic hepatitis | |
| CN101143205A (en) | Traditional Chinese medicine for treating fever due to qi deficiency | |
| CN1117575C (en) | Drug-dropping Chinese patent medicine for improving immunity of human body itself |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |